問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung

Link to Hospital

  • 1,089

    Total Beds

  • 275

    Total Doctors

  • shengyuan@cgmh.org.tw
  • Lin, Sheng-yuan
  • 02-24329292 #2082
  • 204Keelung CityAn LeNo. 222, Maijin Rd., Anle Dist., Keelung City 204015, Taiwan

Recruiting Trial

61Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

174Cases

2022-05-02 - 2026-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-03-31 - 2022-11-30

Phase II

Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy

  • Condition/Disease

    Immunoglobulin A (IgA) Nephropathy

  • Test Drug

    VIS649

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting3Sites

Study ended1Sites

2018-08-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-01-01 - 2024-07-31

Phase III

Completed
A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

  • Test Drug

    Sacituzumab Govitecan

Participate Sites
11Sites

Recruiting11Sites

2024-12-01 - 2028-02-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-05-01 - 2027-06-24

Phase III

Active
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

  • Condition/Disease

    Ischemic Stroke; Ischemic Attack, Transient

  • Test Drug

    錠劑

Participate Sites
12Sites

Recruiting12Sites

2020-08-16 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-08-01 - 2018-12-04

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2025-11-01 - 2028-07-31

Phase III

Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

  • Condition/Disease

    Adult subjects, ≥18 years of age, with a primary diagnosis of MDD who have had an IR to ≥1 oral antidepressant medication (including the subject’s current antidepressant treatment) in the current episode of depression.

  • Test Drug

    tablet

Participate Sites
4Sites

Not yet recruiting4Sites

2025-12-01 - 2028-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

1 2 3 4 5 6 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB